These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis. Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. J Clin Psychiatry; 2022 Jun 20; 83(4):. PubMed ID: 35759785 [Abstract] [Full Text] [Related]
6. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. JAMA Netw Open; 2022 May 02; 5(5):e2211363. PubMed ID: 35536575 [Abstract] [Full Text] [Related]
12. Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose. Follman S, Arora VM, Lyttle C, Moore PQ, Pho MT. JAMA Netw Open; 2019 May 03; 2(5):e193209. PubMed ID: 31050777 [Abstract] [Full Text] [Related]
13. Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US. Han B, Jones CM, Einstein EB, Compton WM. JAMA Netw Open; 2021 Oct 01; 4(10):e2129409. PubMed ID: 34652446 [Abstract] [Full Text] [Related]
14. Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access. Treitler P, Nowels M, Samples H, Crystal S. JAMA Netw Open; 2023 May 01; 6(5):e2312030. PubMed ID: 37145594 [Abstract] [Full Text] [Related]
15. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder. Williams AR, Samples H, Crystal S, Olfson M. Am J Psychiatry; 2020 Feb 01; 177(2):117-124. PubMed ID: 31786933 [Abstract] [Full Text] [Related]
16. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM. JAMA Psychiatry; 2022 Oct 01; 79(10):981-992. PubMed ID: 36044198 [Abstract] [Full Text] [Related]
17. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program. Jakubowski A, Lu T, DiRenno F, Jadow B, Giovanniello A, Nahvi S, Cunningham C, Fox A. J Subst Abuse Treat; 2020 Dec 01; 119():108140. PubMed ID: 33138925 [Abstract] [Full Text] [Related]
18. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014. Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. JAMA Pediatr; 2017 Aug 01; 171(8):747-755. PubMed ID: 28628701 [Abstract] [Full Text] [Related]
19. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper. Bozinoff N, Men S, Kurdyak P, Selby P, Gomes T. JAMA Netw Open; 2022 Sep 01; 5(9):e2234168. PubMed ID: 36173629 [Abstract] [Full Text] [Related]
20. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Park TW, Larochelle MR, Saitz R, Wang N, Bernson D, Walley AY. Addiction; 2020 May 01; 115(5):924-932. PubMed ID: 31916306 [Abstract] [Full Text] [Related] Page: [Next] [New Search]